Charlene S Dezzutti1, Kevin Uranker, Katherine E Bunge, Nicola Richardson-Harman, Ingrid Macio, Sharon L Hillier. 1. *Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA; †Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA; ‡Alpha StatConsult, LLC, Damascus, MD; and §University of Pittsburgh Medical Center, Pittsburgh, PA.
Abstract
OBJECTIVE: Ex vivo HIV-1 challenge has been proposed as a bioindicator of microbicide product effectiveness. The objective of this study was to establish optimal parameters for use of female genital tract tissue in this model. DESIGN: Ex vivo challenge involves in vivo product use, followed by tissue biopsy, and exposure of the tissue to HIV-1 in the laboratory. METHODS: Paired ectocervical and vaginal biopsies were collected from 42 women, and 28 women had additional biopsies from each site collected after 5% lidocaine (n = 14) or chlorhexidine (n = 14) treatment. Tissues were transported immediately to the laboratory and exposed to HIV-1. HIV-1 infection was followed by p24 enzyme-linked immunosorbent assay on culture supernatants and at study end after weighing and fixing the tissue for immunohistochemistry to detect p24 expressing cells. RESULTS: Although both tissue types were equally infected with HIV-1 based on the immunohistochemistry results, ectocervical tissues had significantly higher HIV-1 replication than vaginal tissues (P < 0.005). Lidocaine and chlorhexidine had minimal impact on HIV-1 infection and replication. Point estimates for p24 levels were defined for 95% probability of p24-positive tissues and were 3.43 log10 for ectocervical tissue and 2.50 log10 for vaginal tissue based on the weight-adjusted cumulative p24 end points. CONCLUSIONS: Although similar proportions of ectocervical and vaginal tissues support HIV-1 infection, higher levels of HIV-1 replication were observed in ectocervical tissues. Defining point estimates for HIV-1 infection in fresh ectocervical and vaginal tissues provides valuable information for the evaluation of HIV-1 preventative treatments during early clinical studies.
OBJECTIVE: Ex vivo HIV-1 challenge has been proposed as a bioindicator of microbicide product effectiveness. The objective of this study was to establish optimal parameters for use of female genital tract tissue in this model. DESIGN: Ex vivo challenge involves in vivo product use, followed by tissue biopsy, and exposure of the tissue to HIV-1 in the laboratory. METHODS: Paired ectocervical and vaginal biopsies were collected from 42 women, and 28 women had additional biopsies from each site collected after 5% lidocaine (n = 14) or chlorhexidine (n = 14) treatment. Tissues were transported immediately to the laboratory and exposed to HIV-1. HIV-1 infection was followed by p24 enzyme-linked immunosorbent assay on culture supernatants and at study end after weighing and fixing the tissue for immunohistochemistry to detect p24 expressing cells. RESULTS: Although both tissue types were equally infected with HIV-1 based on the immunohistochemistry results, ectocervical tissues had significantly higher HIV-1 replication than vaginal tissues (P < 0.005). Lidocaine and chlorhexidine had minimal impact on HIV-1 infection and replication. Point estimates for p24 levels were defined for 95% probability of p24-positive tissues and were 3.43 log10 for ectocervical tissue and 2.50 log10 for vaginal tissue based on the weight-adjusted cumulative p24 end points. CONCLUSIONS: Although similar proportions of ectocervical and vaginal tissues support HIV-1 infection, higher levels of HIV-1 replication were observed in ectocervical tissues. Defining point estimates for HIV-1 infection in fresh ectocervical and vaginal tissues provides valuable information for the evaluation of HIV-1 preventative treatments during early clinical studies.
Authors: Phalguni Gupta; Deena Ratner; Bruce K Patterson; Kathy Kulka; Lisa C Rohan; Michael A Parniak; Charles E Isaacs; Sharon Hillier Journal: AIDS Res Hum Retroviruses Date: 2006-05 Impact factor: 2.205
Authors: Sheila R Abner; Patricia C Guenthner; Jeannette Guarner; Kelly A Hancock; James E Cummins; Aaron Fink; G Thomas Gilmore; Charles Staley; Albert Ward; Odessa Ali; Sander Binderow; Stephen Cohen; Lisa A Grohskopf; Lynn Paxton; Clyde E Hart; Charlene S Dezzutti Journal: J Infect Dis Date: 2005-09-26 Impact factor: 5.226
Authors: P A Marx; A I Spira; A Gettie; P J Dailey; R S Veazey; A A Lackner; C J Mahoney; C J Miller; L E Claypool; D D Ho; N J Alexander Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Patrick Barnable; Giulia Calenda; Thierry Bonnaire; Radhika Menon; Keith Levendosky; Agegnehu Gettie; James Blanchard; Michael L Cooney; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191
Authors: Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-02-10 Impact factor: 2.205
Authors: Louise A Ouattara; Patrick Barnable; Paul Mawson; Samantha Seidor; Thomas M Zydowsky; Larisa Kizima; Aixa Rodriguez; José A Fernández-Romero; Michael L Cooney; Kevin D Roberts; Agegnehu Gettie; James Blanchard; Melissa Robbiani; Natalia Teleshova Journal: Antimicrob Agents Chemother Date: 2014-03-10 Impact factor: 5.191
Authors: Katherine E Bunge; Charlene S Dezzutti; Lisa C Rohan; Craig W Hendrix; Mark A Marzinke; Nicola Richardson-Harman; Bernard J Moncla; Brid Devlin; Leslie A Meyn; Hans M L Spiegel; Sharon L Hillier Journal: J Acquir Immune Defic Syndr Date: 2016-04-15 Impact factor: 3.731
Authors: Betsy C Herold; Beatrice A Chen; Robert A Salata; Mark A Marzinke; Clifton W Kelly; Charlene S Dezzutti; Ian McGowan; Beth Galaska; Lisa Levy; Jeanna M Piper; Sharon Hillier; Craig W Hendrix Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079